UNSPSC 51273924: Bupivacaine/epinephrine/lidocaine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.

UNSPSC 51273924 Bupivacaine/epinephrine/lidocaine (Commodity) shows limited recent state and local procurement activity directly aligned with the code's nominal scope. The three most recent opportunities posted under this code do not track the anesthetic product line the code names; instead, they cover naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products broadly. The mismatch between code assignment and actual scope suggests either misclassification in the underlying procurement system or that the code is used as a catch-all for pharmaceutical procurement when more specific Commodity codes do not fit the need. State and local buyers using this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and cooperative purchasing alliances serving multi-state and multi-jurisdiction membership (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP).

Recent activity spans Florida, Texas, and Minnesota through a cooperative vehicle that extends to Oregon. Seminole County issued an IFB (Solicitation IFB60459723LAS, response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year contract with one-year renewal option. The Texas HHS Commission issued an RFI (HHS0017013, posted April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities before developing a formal RFP. MMCAP, administered by Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities, with awarded vendors effective July 1, 2026 and a two-year initial contract term. The code shows sparse, dispersed activity with no standout repeat buyers or consolidated procurement volume signals in the recent record.